Key facts
- It has raised $2.3M; the latest was Early Stage VC in Dec 2024.
- Notable investors include Tech Incubator Program for Startup, Center for Creative Economy and Innovation, Eyegene, K-Bio Bridge, Myriad Life Sciences — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for MediciBIO
- ·The full record, as it builds
Funding rounds
No funding rounds for MediciBIO are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MediciBIO
Developer of a gene therapeutic technology designed for healthcare professionals. The company's platform uses gene therapy technology for the delivery of various gene therapeutics such as mRNA, self-amplifying mRNA, Cas9 mRNA, siRNA, and ASO (antisense oligonucleotide) via Ionizable and Targeting Lipids, enabling medical practitioners to treat genetic diseases.
- Sector
- Healthcare
- HQ
- Yongin, South Korea
- Founded
- 2021
- Employees
- 9
- Website
- medicibio.com/
- Ownership
- Privately Held (backing)
MediciBIO doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MediciBIO shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MediciBIO in its N-PORT filings yet. We sweep new filings monthly.